Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H₂ Mab-77-mG_2a -f.

ABSTRACT: Breast cancer patients with high levels of human epidermal growth factor receptor 2 (HER2) expression have worse clinical outcomes. Anti-HER2 monoclonal antibody (mAb) is the most important therapeutic modality for HER2-positive breast cancer. We previously immunized mice with the ectodomain of HER2 to create the anti-HER2 mAb, H₂ Mab-77 (mouse IgG₁ , kappa). This was then altered to produce H₂ Mab-77-mG_2a -f, an afucosylated mouse IgG_2a . In the present work, we examined the reactivity of H₂ Mab-77-mG_2a -f and antitumor effects against breast cancers in vitro and in vivo. BT-474, an endogenously HER2-expressing breast cancer cell line, was identified by H₂ Mab-77-mG_2a -f with a strong bindin

SUBMITTER: Tanaka T 

PROVIDER: S-EPMC10823288 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature